Praxis Precision Medicines annual r&d spending
2019
2020
2021
2022
2023
2024
2025
Praxis Precision Medicines R&D Spending Growth & History (PRAX)
Praxis Precision Medicines's r&d spending was $267.1M for fiscal 2025.
View full Praxis Precision Medicines company overviewPraxis Precision Medicines annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $267.1M | $114.7M | +75.26% |
| 2024 | 2024-12-31 | $152.4M | $65.6M | +75.66% |
| 2023 | 2023-12-31 | $86.8M | −$68.3M | −44.04% |
| 2022 | 2022-12-31 | $155.0M | $34.8M | +28.92% |
| 2021 | 2021-12-31 | $120.3M | $75.3M | +167.38% |
| 2020 | 2020-12-31 | $45.0M | $15.4M | +52.17% |
| 2019 | 2019-12-31 | $29.6M | — | — |
Praxis Precision Medicines quarterly r&d spending
Q3.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $69.4M | $6.4M | +10.17% |
| Q1 2026 | 2026-03-31 | $78.0M | $17.2M | +28.26% |
| Q4 2025 | 2025-12-31 | $77.5M | $21.2M | +37.70% |
| Q3 2025 | 2025-09-30 | $65.8M | $23.9M | +57.10% |
| Q2 2025 | 2025-06-30 | $63.0M | $35.7M | +131.13% |
| Q1 2025 | 2025-03-31 | $60.8M | $33.8M | +125.34% |
| Q4 2024 | 2024-12-31 | $56.3M | $37.9M | +206.11% |
| Q3 2024 | 2024-09-30 | $41.9M | $24.6M | +142.65% |
| Q2 2024 | 2024-06-30 | $27.3M | $1.6M | +6.43% |
| Q1 2024 | 2024-03-31 | $27.0M | $1.5M | +5.80% |
| Q4 2023 | 2023-12-31 | $18.4M | −$9.9M | −35.09% |
| Q3 2023 | 2023-09-30 | $17.3M | −$13.2M | −43.30% |
| Q2 2023 | 2023-06-30 | $25.6M | −$18.0M | −41.28% |
| Q1 2023 | 2023-03-31 | $25.5M | −$27.1M | −51.56% |
| Q4 2022 | 2022-12-31 | $28.3M | −$15.2M | −34.89% |
| Q3 2022 | 2022-09-30 | $30.4M | −$2.7M | −8.15% |
| Q2 2022 | 2022-06-30 | $43.6M | $17.9M | +69.87% |
| Q1 2022 | 2022-03-31 | $52.7M | $34.7M | +193.67% |
| Q4 2021 | 2021-12-31 | $43.5M | $27.2M | +167.40% |
| Q3 2021 | 2021-09-30 | $33.1M | $20.4M | +159.18% |
| Q2 2021 | 2021-06-30 | $25.7M | $16.6M | +183.73% |
| Q1 2021 | 2021-03-31 | $17.9M | $11.1M | +161.05% |
| Q4 2020 | 2020-12-31 | $16.3M | — | — |
| Q3 2020 | 2020-09-30 | $12.8M | $3.4M | +36.81% |
| Q2 2020 | 2020-06-30 | $9.1M | — | — |
| Q1 2020 | 2020-03-31 | $6.9M | — | — |
| Q3 2019 | 2019-09-30 | $9.3M | — | — |
Praxis Precision Medicines r&d spending trends
Over the last five fiscal years, Praxis Precision Medicines's r&d spending increased from $45.0M to $267.1M, a change of $222.1M. The latest reported quarter, Q2 2026, shows $69.4M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Praxis Precision Medicines source filings ↗